Evidence map›Paper›PMID 33275950›Full record

SynthesisThe Lancet. Global health2021

Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study.

GBD 2019 Blindness and Vision Impairment Collaborators, Vision Loss Expert Group of the Global Burden of Disease Study

3 registry-linked trialsOpen access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in The Lancet. Global health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 617 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
617citing papers in PubMed, 8 pooled it
88.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05740904 nacompletednot on this mapstarted 2023, after this paper: background citation

Efficacy and Safety of New Defocus Spectacle Lens in Preventing Progression of Myopia Compared With the Conventional Single-vision Spectacle Lens: a Randomized Controlled Trial Among Chinese Children

TypeinterventionalSponsorZhongshan Ophthalmic Center, Sun Yat-sen UniversityRan2023 to 2024Enrolled174ConditionsMyopiaArmsNew defocus spectacle lenses, Convenional aspheric single-vision spectacle lenses
NCT06065631 naterminatednot on this mapstarted 2023, after this paper: background citation

Seeing to Learn in Sierra Leone: Impact of Spectacle Correction on Children's Academic Performance and Mental Health Wellbeing

TypeinterventionalSponsorUniversity of MinnesotaRan2023 to 2025Enrolled1,821ConditionsRefractive ErrorsArmsEyeglasses, Prescription slip
NCT07218991 narecruitingnot on this mapstarted 2025, after this paper: background citation

Wearable Echolocation Aids Using Parametric Sound

TypeinterventionalSponsorThe University of Texas Medical Branch, GalvestonRan2025 to 2028Enrolled50ConditionsLow VisionArmsWearable Echolocation Device
3 · Its place in the literature

Who cites it

617 citing papers in PubMed, 8 syntheses or guidelines pooled it, 1,289 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

557 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 20 institutions in 30 countries.

GBD 2019 Blindness and Vision Impairment Collaborators
Vision Loss Expert Group of the Global Burden of Disease Study
Anglia Ruskin University · GBBill & Melinda Gates Foundation · USInstituto da Visão · BRUniversity of Washington · USFred Hollows Foundation · AUDatta Meghe Institute of Medical Sciences · INIran University of Medical Sciences · IRHarvard University Press · USDuy Tan University · VNHamad bin Khalifa University · QAImperial College London · GBJahrom University · IRMashhad University of Medical Sciences · IRMcMaster University · CAShahid Beheshti University of Medical Sciences · IRUniversity of Gondar · ETUniversity of Michigan–Ann Arbor · USUNSW Sydney · AUAll India Institute of Medical Sciences · INBabol University of Medical Sciences · IR

Funding

Endothelial Transmigration in Neovascular Age-related Macular DegenerationR01EY017011 · NEI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HARTNETT, MARY ELIZABETH RUTH · 2007 to 2025
$7.7M
Mechanisms of Angiogenesis of Retinopathy of PrematurityR01EY015130 · NEI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Mary Elizabeth Ruth Hartnett · 2005 to 2026
$7.6M
Communication About Glaucoma and Patient OutcomesR01EY018400 · NEI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SLEATH, BETSY LYNN · 2009 to 2012
$2.6M
Department of Health HTA 09/104/40NEI NIH HHS R01 EY015130NEI NIH HHS R01 EY017011NEI NIH HHS R01 EY018400
6 · The paper itself

Abstract

backgroundTo contribute to the WHO initiative, VISION 2020: The Right to Sight, an assessment of global vision impairment in 2020 and temporal change is needed. We aimed to extensively update estimates of global vision loss burden, presenting estimates for 2020, temporal change over three decades between 1990-2020, and forecasts for 2050.

methodsWe did a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, to October, 2018. Only studies with samples representative of the population and with clearly defined visual acuity testing protocols were included. We fitted hierarchical models to estimate 2020 prevalence (with 95% uncertainty intervals [UIs]) of mild vision impairment (presenting visual acuity ≥6/18 and <6/12), moderate and severe vision impairment (<6/18 to 3/60), and blindness (<3/60 or less than 10° visual field around central fixation); and vision impairment from uncorrected presbyopia (presenting near vision <N6 or <N8 at 40 cm where best-corrected distance visual acuity is ≥6/12). We forecast estimates of vision loss up to 2050.

findingsIn 2020, an estimated 43·3 million (95% UI 37·6-48·4) people were blind, of whom 23·9 million (55%; 20·8-26·8) were estimated to be female. We estimated 295 million (267-325) people to have moderate and severe vision impairment, of whom 163 million (55%; 147-179) were female; 258 million (233-285) to have mild vision impairment, of whom 142 million (55%; 128-157) were female; and 510 million (371-667) to have visual impairment from uncorrected presbyopia, of whom 280 million (55%; 205-365) were female. Globally, between 1990 and 2020, among adults aged 50 years or older, age-standardised prevalence of blindness decreased by 28·5% (-29·4 to -27·7) and prevalence of mild vision impairment decreased slightly (-0·3%, -0·8 to -0·2), whereas prevalence of moderate and severe vision impairment increased slightly (2·5%, 1·9 to 3·2; insufficient data were available to calculate this statistic for vision impairment from uncorrected presbyopia). In this period, the number of people who were blind increased by 50·6% (47·8 to 53·4) and the number with moderate and severe vision impairment increased by 91·7% (87·6 to 95·8). By 2050, we predict 61·0 million (52·9 to 69·3) people will be blind, 474 million (428 to 518) will have moderate and severe vision impairment, 360 million (322 to 400) will have mild vision impairment, and 866 million (629 to 1150) will have uncorrected presbyopia.

interpretationAge-adjusted prevalence of blindness has reduced over the past three decades, yet due to population growth, progress is not keeping pace with needs. We face enormous challenges in avoiding vision impairment as the global population grows and ages.

fundingBrien Holden Vision Institute, Fondation Thea, Fred Hollows Foundation, Bill & Melinda Gates Foundation, Lions Clubs International Foundation, Sightsavers International, and University of Heidelberg.

Indexed as

Global Burden of DiseaseGlobal HealthVisual AcuityAgedAged, 80 and overBlindnessCataractEye DiseasesFemaleForecastingGlaucomaHumansMacular DegenerationMaleMiddle AgedPresbyopia

Identifiers

PMID33275950
PMCPMC7820390
OpenAlexW3110054227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.